<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1175">
  <stage>Registered</stage>
  <submitdate>26/05/2006</submitdate>
  <approvaldate>26/05/2006</approvaldate>
  <nctid>NCT00331123</nctid>
  <trial_identification>
    <studytitle>Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido</studytitle>
    <scientifictitle>Study to Evaluate Efficacy and Safety of Transdermal Testosterone and Safety for an Open-label Period in Women With Hypoactive Sexual Desire Disorder on Estrogen Replacement Therapy and Undergone Hysterectomy/Bilateral Oophorectomy.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2001133 and Yr 2-4 OL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypoactive Sexual Desire Disorder</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Testosterone Transdermal System
Treatment: drugs - Placebo

Placebo Comparator: Placebo - Placebo patch

Experimental: Testosterone Patch - 


Treatment: drugs: Testosterone Transdermal System
testosterone patch, 300mcg/day, changed every 3-4 days for up to 52 weeks

Treatment: drugs: Placebo
placebo patch,changed every 3-4 days for 24 weeks during double blind phase

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the efficacy of testosterone transdermal system (TTS) as measured by the change from baseline in the frequency of total satisfying sexual activity captured by the Sexual Activity Log (SAL).</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the efficacy measured by the change from baseline in sexual desire; personal distress as measured by the Personal Distress Scale score; the other 6 domains of the profile of Female Sexual Function; and the other 8 SAL endpoints.</outcome>
      <timepoint>24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Eligible women must:

          1. Be 20-70 years old and in generally good health

          2. Have undergone hysterectomy and removal of both ovaries at least 6 months prior to
             screening

          3. Be receiving a stable dose of estrogen replacement therapy for at least 3 months prior
             to screening with the intention of maintaining that regimen.

          4. Be, in her own judgment, in a stable monogamous sexual relationship that is perceived
             to be secure and communicative, for at least one year prior to study entry.

          5. Meet the criteria for having hypoactive sexual desire disorder.</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Eligible women must not:

          1. Have received androgen therapy at any time during the past 3 months (during the past 7
             months if therapy was an investigational implantable product)

          2. Be experiencing any chronic or acute life stress relating to any major life change

          3. Be experiencing depression and/or receiving medication for such illness or disorder

          4. Have current severe skin problems (such as severe or cystic acne) or allergy to
             adhesives (like the ones in bandages)

          5. Have had a major illness, active gall bladder disease, or gynecological or breast
             surgery within the last 6 months

          6. Have a history of breast, endometrial, or other gynecological cancer any time before
             study participation or other cancer within the last 5 years

          7. Have diabetes, a history of cerebrovascular disease, thromboembolic disorders, heart
             attack, or angina at any time before study participation or thrombophlebitis within
             the last 5 years

          8. Have abnormal laboratory test results upon initial screening for this study

          9. Have previously participated in P&amp;GP study 1999068 or 1999092

         10. Have previously participated in a clinical trial within 30 days or received an
             investigation medication within 30 days.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>562</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Research Site - Prahran</hospital>
    <postcode> - Prahran</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Warner Chilcott</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is designed to evaluate efficacy and safety of a testosterone patch as treatment
      for low libido in surgically menopausal women who are taking estrogen therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00331123</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Johna Lucus, MD</name>
      <address>Procter and Gamble</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>